Literature DB >> 22843915

Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma.

Eun-Joo Jung1, Chun-Geun Ryu, Gangmi Kim, Su Ran Kim, Hee Sun Park, Young Jun Kim, Dae-Yong Hwang.   

Abstract

AIM: The aim of this study was to evaluate changes in splenic size and platelet counts, in patients with colorectal cancer during oxaliplatin based chemotherapy, and to determine their clinical significance. PATIENTS AND METHODS: The prospectively archived records of 50 patients with colorectal cancer that received oxaliplatin-based chemotherapy were reviewed.
RESULTS: Thirty-eight men and 12 women, of median age 58 (range 35-77) years, were enrolled. Median spleen volume ratios were 1.3-fold after 6 cycles and 1.9-fold after 12 cycles. The incidence of splenomegaly was 30% after 6 cycles and 67% after 12 cycles, and of thrombocytopenia was 70% after 6 cycles, 82% after 9 cycles, and 80% after 12 cycles. Thrombocytopenia was found to be related to splenomegaly, and this pattern was notable after 6 cycles of chemotherapy.
CONCLUSION: Splenic enlargement and reduction in platelet counts were common during chemotherapy. Furthermore, these changes were found to occur rapidly after 6 cycles of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843915

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Assessing splenic enlargement on CT by unidimensional measurement changes in patients with colorectal liver metastases.

Authors:  Breanna J Joiner; Amber L Simpson; Julie N Leal; Michael I D'Angelica; Richard K G Do
Journal:  Abdom Imaging       Date:  2015-10

2.  Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.

Authors:  Rika Saito; Yasuyuki Kawamoto; Mutsumi Nishida; Takahito Iwai; Yasuka Kikuchi; Isao Yokota; Ryo Takagi; Takahiro Yamamura; Ken Ito; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
Journal:  Int J Clin Oncol       Date:  2022-08-30       Impact factor: 3.850

3.  Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.

Authors:  Francesca Castagnoli; Simon Doran; Jason Lunn; Anna Minchom; Mary O'Brien; Sanjay Popat; Christina Messiou; Dow-Mu Koh
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

4.  Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity.

Authors:  Youssef Bouferraa; Yolla Haibe; Elio Jabra; Maya Charafeddine; Malek Kreidieh; Randa Raad; Sally Temraz; Deborah Mukherji; Firas Ershaid; Nadim Muallem; Walid Faraj; Mohamad Khalife; Rania A Eid; Ali Shamseddine
Journal:  J Clin Exp Hepatol       Date:  2021-06-15

5.  The correlation between preoperative volumetry and real graft weight: comparison of two volumetry programs.

Authors:  Nadiar Mussin; Marco Sumo; Kwang-Woong Lee; YoungRok Choi; Jin Yong Choi; Sung-Woo Ahn; Kyung Chul Yoon; Hyo-Sin Kim; Suk Kyun Hong; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Ann Surg Treat Res       Date:  2017-03-24       Impact factor: 1.859

6.  Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.

Authors:  Ryo Ohta; Takeshi Yamada; Keisuke Hara; Takuma Iwai; Kohji Tanakaya; Keiichiro Ishibashi; Kazuhiko Yoshimatsu; Chihiro Kosugi; Masahiro Tsubaki; Hideo Nakajima; Masatoshi Oya; Hiroshi Yoshida; Keiji Koda; Hideyuki Ishida
Journal:  Int J Clin Oncol       Date:  2020-08-12       Impact factor: 3.402

7.  von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.

Authors:  Naoto Nishigori; Masanori Matsumoto; Fumikazu Koyama; Masaki Hayakawa; Kinta Hatakeyayama; Saiho Ko; Yoshihiro Fujimura; Yoshiyuki Nakajima
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

8.  Partial splenic embolization to permit continuation of systemic chemotherapy.

Authors:  Jose Hugo M Luz; Paula M Luz; Edson Marchiori; Leonardo A Rodrigues; Hugo R Gouveia; Henrique S Martin; Igor M Faria; Roberto R Souza; Roberto de Almeida Gil; Alexandre de M Palladino; Karina B Pimenta; Henrique S de Souza
Journal:  Cancer Med       Date:  2016-09-09       Impact factor: 4.452

9.  Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.

Authors:  Mi-Jung Kim; Sae-Won Han; Dae-Won Lee; Yongjun Cha; Kyung-Hun Lee; Tae-Yong Kim; Do-Youn Oh; Se Hyung Kim; Seock-Ah Im; Yung-Jue Bang; Tae-You Kim
Journal:  Cancer Res Treat       Date:  2016-01-14       Impact factor: 4.679

10.  Increase in spleen volume as a predictor of oxaliplatin toxicity.

Authors:  Alissar El Chediak; Ali A Haydar; Ayman Hakim; Sarah Abdel Massih; Lara Hilal; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Ther Clin Risk Manag       Date:  2018-04-11       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.